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Abstract-Effects
of single and repeated administration of pentazocine (5 times at intervals of 3-4 days) were compared with those of morphine and methamphetamine by means of ambulatory activity in mice. The interactions among these 3 drugs were also investigated.
Pentazocine (25 mg/kg, s.c.), morphine (10 and 20 mg/kg, s.c.) and methamphetamine (2 mg/kg, s.c.) significantly increased the activity, and the effect progressively enhanced (defined here as development of reverse tolerance) during the repeated administration schedule.
The induction of reverse tolerance to pentazocine was less dependent on the environmental conditions, and it was abol ished within 2 months.
A cross reverse tolerance was demonstrated from meth amphetamine to pentazocine and to morphine, and from morphine to pentazocine. However, no significant cross reverse tolerance was induced from pentazocine to morphine and to methamphetamine, and from morphine to methamphetamine. The present results suggest that pentazocine possesses an ambulation-increasing effect, although the characteristics are different from that of either morphine or metham phetamine.
Pentazocine, a benzomorphan derivative, is a mixed opiate agonist-antagonist, and this drug has been widely used in clinical therapy as an analgesic.
Recently, however, some problems, including psychotomimetic effects, have been pointed out (1-3). Pentazocine has been considered to have actions on dopamine receptors as well as opiate recep tors (4, 5).
On the other hand, both morphine, an opiate agonist, and methamphetamine, an indirect agonist on dopamine receptors, in crease the ambulatory activity of mice; and an enhancement of the ambulation-increasing effect, defined here as reverse tolerance, is elicited when these drugs are repeatedly ad ministered at intervals of longer than 1 day (6, 7). However, these experiments also indicated that the methamphetamine and morphine-induced reverse tolerances were partially different in their characteristics. Fur thermore, it has been demonstrated that a cross reverse tolerance from methamphet amine to morphine is easily produced, but hardly produced from methamphetamine to morphine (8).
The characteristics of the behavior-stimu lant effect of pentazocine have been insuf ficiently investigated, although it possesses actions on the dopamine systems (4, 5). Hence, the purposes of this experiment were to study the effects of single and repeated ad ministration of pentazocine by means of ambulatory activity in mice, and the effects were compared with those of morphine and methamphetamine.
In addition, interactions among these 3 drugs were also investigated.
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Materials and Methods

Animals
Male ddY strain mice (Japan Laboratory Animal) were used at the age of 7 weeks and the weight of 28-35 g. During the experi mental period, the illumination (light period 6 a.m.-6 p.m.) and temperature (22±2'C) of the breeding room were controlled.
Drugs
The drugs used were pentazocine (Pen tagin Inj.®: Sankyo Pharm.), morphine HCI (Takeda Chem.) and methamphetamine HCI (Dainippon Pharm.). These drugs were dis solved in or diluted by physiological saline and administered subcutaneously (s.c.) at a fixed volume of 0.1 ml/10 g body weight of the mouse regardless of the drug doses.
Ambulation measurement
The ambulatory activity of a mouse was measured by a tilting-type ambulometer (AMB-10, O'Hara & Co.). Ten mice were in dividually put into activity cages; and after an adaptation period of 30 min, the drug ad ministration was conducted. The ambulatory activity of each mouse was measured for 3 hr after the drug administration.
Repeated administration schedules: Mice were treated with either pentazocine (6.25 or 25 mg/kg), morphine (10 or 20 mg/kg), methamphetamine (2 mg/kg) or saline 5 times at intervals of 3-4 days.
Four days after the 5th drug injection, the following drug administrations were con ducted: 1) One group of mice that had experi enced 5 times administration of pentazocine (25 mg/kg) had been kept for 2 months without any treatment. Then, they were read ministered the same dose of pentazocine. 2) Cross administration of pentazocine (25 mg/ kg) was conducted in mice that had ex perienced either saline, morphine (10 and 20 mg/kg) or methamphetamine (2 mg/kg). 3) Cross administration of morphine (20 mg/kg) was conducted in mice that had experienced either saline, pentazocine (6.25 and 25 mg/ kg) or methamphetamine (2 mg/kg). 4) Cross administration of methamphetamine (2 mg/ kg) was conducted in mice that had experi enced either saline, pentazocine (6.25 and 25 mg/kg) or morphine (10 and 20 mg/kg). The administration of pentazocine, morphine and methamphetamine, at the doses equiva lent with those injected in the cross admin istration schedule, were also carried out in the drug-naive and age-adjusted mice. Repeated pentazocine treatment in a small jar: Mice were treated with pentazocine (25 mg/kg) or saline 4 times at intervals of 3-4 days, and they were individually put into small glass jars (5.5-cm in diameter) for 3 hr. In the jar, the mouse's ambulatory movement was perfectly restricted. Four days after the 4th administration, these mice were given pen tazocine (25 mg/kg) in the activity cage.
The doses of morphine and methamphet amine and the number and intervals of their repeated administration were considered to be optimum according to our previous studies (6-8).
The experiment of the ambulatory activity measurement was held between 10 a.m.-5 p.m. In each experiment, 16-20 mice were used.
Statistical analysis
The overall variance of the mean ambula tory activity counts for 3 hr were analyzed. In a case of significant variance, Student's t test and/or the Cochran-Cox test were ap plied to compare mean values. When P values were equal to or less than 0.05, they were defined to be significantly different.
Results Figure 1 shows the temporal changes in mean ambulatory activity counts after ad ministration of saline, pentazocine (6.25 and 25 mg/kg), morphine (10 and 20 mg/kg) and methamphetamine (2 mg/kg) to the drug-naive mice. Pentazocine scarcely changes the ambulatory activity at 6.25 mg/ kg, but markedly increased it at 25 mg/kg. The ambulation-increasing effect attained its maximum level at 20-30 min and persisted for about 1 hr. Morphine and methamphet amine increased the activity with the maxi mum effect at 30-40 min and duration for longer than 2 hr after the administration. Figure 2 shows the mean overall ambula tory activity counts for 3 hr after the repeated 5 times administration of saline, pentazocine (6.25 and 25 mg/kg), morphine (10 and 20 mg/kg) and methamphetamine (2 mg/kg). The ambulatory activity counts slightly but significantly decreased when saline was re peatedly administered.
The repeated ad ministration of pentazocine (6.25 mg/kg) caused no marked change in the activity counts throughout the repeated administra tion. However, the repeated administration of pentazocine (25 mg/kg), morphine (20 mg/ kg) and methamphetamine (2 mg/kg) elicited a progressive enhancement of their ambula tion-increasing effect. The ambulation-in creasing effect of morphine (10 mg/kg) also increased during the repeated administration, although such a change did not reach a significant level. Fig. 1 . Temporal changes in ambulatory activity counts after administration of saline, pentazocine (6.25 and 25 mg/kg), morphine (10 and 20 mg/kg) and methamphetamine (2 mg/kg) to the drug-naive mice. Each drug dose or saline was administered subcutaneously (s.c.) after an adaptation period of 30 min for the activity cage, and cumulative activity counts during 10 min segments were recorded for 3 hr thereafter. Numbers of mice used were 30 in the saline-, pentazocine and morphine-administered groups and 20 in the methamphetamine-administered groups. The reverse tolerance to the ambulation increasing effect of pentazocine was almost completely abolished by 2 months after the cessation (data not shown). Figure 3 shows the data obtained in the cross administration schedules. There was no significant difference in the activity counts between the drug-naive and saline-experi enced mice after administration of penta zocine, morphine and methamphetamine. When pentazocine (25 mg/kg) was cross administered to the morphine and metham phetamine-experienced mice, they demon strated significantly higher activity counts than the saline-experienced mice (upper panel). Methamphetamine-experienced mice, but not pentazocine-experienced mice, showed an increased sensitivity to the ambu lation-increasing effect of morphine (20 mg/ kg) (middle panel). On the other hand, neither pentazocine-experienced mice nor morphine-experienced mice exhibited a significant increase in the sensitivity to the ambulation-increasing effect of methamphet amine (2 mg/kg) (lower panel). Figure 4 shows mean overall ambulatory activity counts for 3 hr after administration of pentazocine (25 mg/kg) to the mice that had been treated with pentazocine or saline in the small glass jar. The repeated treatment with pentazocine in the small jar induced a reverse tolerance to its ambulation-increasing effect. Thus, the mean overall ambulatory activity counts were almost identical in the groups of mice that had experienced pentazocine in the activity cage and the small glass jar.
Discussion
The present experiment demonstrated that a comparatively higher dose of pentazocine (i.e., 25 mg/kg) increased the mouse's ambu latory activity. It has been considered that pentazocine acts as an antagonist on the mu receptor site, but acts as an agonist on the kappa and sigma-receptor sites (9). It has been also shown that opioid-induced hyper activity originates through agonistic action on the mu and sigma-receptor sites (10). Furthermore, pentazocine has been reported to possess a direct agonistic action on dopa mine receptors (4, 5). It is therefore con sidered that opiate systems as well as dopa mine systems are involved in the pentazocine induced increase in the ambulatory activity in mice. On the other hand, the hyperactivity induced by morphine and methamphetamine has been reported to be mainly due to the following mechanisms: Morphine indirectly stimulates catecholaminergic systems through an agonistic action on opiate systems, in particular the mu-receptor site (11-13). Methamphetamine indirectly stimulates cate cholaminergic systems through facilitation of the release as well as inhibition of reuptake of the neurotransmitters (14).
The present experiment revealed that the repeated administration of pentazocine in duced a reverse tolerance to its ambulation increasing effect in mice. This result is similar to that reported in rats (15). Such an enhance ment of the effect is hardly attributable to an accumulation of pentazocine. This is not only because administered pentazocine is almost completely metabolized in the liver and ex creted in the urine with a plasma half-life of 2-3 hr (9), but because the repeated ad ministration of the small dose (6.25 mg/kg) produced no marked change in the activity throughout the administration schedule. It is therefore reasonable to consider that the enhancement of the effect of pentazocine is induced through a mechanism that is parti ally similar to those involved in the reverse tolerance to the ambulation-increasing effect of morphine (7) and methamphetamine (6, 16). Since the reverse tolerance to metham phetamine in animals is closely related with amphetamine psychosis in humans (17), there is also a possibility that the reverse tolerance to pentazocine is related to the development of psychotomimetic symptoms during chronic use of pentazocine (1-3) .
The development of cross reverse tolerance was dependent on the drug combinations. Thus, an increased sensitivity to pentazocine was induced in the methamphetamine-experi enced mice. However, the pentazocine experienced mice demonstrated no signifi cant change in the sensitivity to methamphet amine. These characteristics of the interac tion between pentazocine and methamphet amine are similar to those between morphine and methamphetamine as demonstrated in this and previous experiments (8). However, the pentazocine-experienced mice failed to exhibit any cross reverse tolerance to mor phine, although the morphine-experienced mice showed an increased sensitivity to pentazocine.
This finding suggests that the behavioral characteristics of pentazocine are different from those of either morphine or methamphetamine when the mouse's ambu latory activity is used as the indicator of the drug effects. Sansone et al. (18) also showed that the pentazocine-induced hyperactivity in mice was not specifically related to opioid mechanisms.
It is difficult to elucidate the detailed mechanism involved in the cross reverse tolerances observed in the present experiment.
However, there is a possibility that the mice were able to discriminate be tween the effects of these 3 drugs.
The difference of the characteristics be tween the reverse tolerance to pentazocine and those to methamphetamine and morphine can be demonstrated by the following find ings. The reverse tolerance to pentazocine was induced in the mice that had experienced the drug in either the activity cage or the small jar, indicating that the effect was in dependent of the environmental condition. In addition, the established reverse tolerance to pentazocine is almost reversible. The reverse tolerance to the ambulation-increasing effect of methamphetamine and morphine could be induced in a freely movable situation (6, 7). Furthermore, the reverse tolerance to metham phetamine once established was perfectly irreversible (6). The reverse-tolerance to mor phine was reversible, but an increased sensitivity was partially maintained for longer than 2 months (7). The differences among the 3 drugs might be due to pentazocine's ability to directly act on both opiate and dopa mine systems (4, 5, 9, 10). However, a further experiment is required to determine what mechanism is dominant in the ambulation increasing effect of pentazocine.
